Browsing by Author "Ragab, Mai F."

Filter results by typing the first few letters
Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    Comparison Between the Pharmacokinetics Data of Ketorolac Tromethamine Wafer a Novel Drug Delivery System and Conventional Ketorolac Tromethamine Tablets to Enhance Patient Compliance Using a New LC-MS/MS Method
    (Springer, 3/26/2020) Abd Elaty Mostafa, Dalia; Mostafa Hashad, Amira; Ragab, Mai F.; Wagdy, Hebatallah A
    potent and widely used non-steroidal anti-inflammatory drug. Despite its efficacy, it causes gastric irritation and increases the risk of gastrointestinal injuries. This study aimed to formulate KTM wafer to overcome its harmful gastrointestinal side effects. By solvent evaporation method six formulae prepared with different concentrations of polymers of sodium carboxymethyl cellulose, sodium alginate, and hydroxypropyl methylcellulose (HPMC E15). The formula F2 with high concentration of sodium alginate wafer, shows disintegration time in 85 s, with pH 6.6,% drug loaded with 102% and high dissolution release rate in 20 min. Drug release pattern appears to be second order. The mean Cpmax values of F2 wafer and the marketed product were 2135.47 ± 13.83 ng/mL and 1073 ± 23.5, respectively. The median values of Tmax were 1 and 3 h, respectively. The calculated AUC0 − ∞values were 2087 ± 71.58 and 3981 ± 62.34 ng h/mL for F2 and marketed product, correspondingly. The relative bioavailability was found to be 0.52. A new rapid, sensitive, and specific LC-MS/MS fully validated method was developed for the determination and quantification of KTM, using torsemide as internal standard, in biological sample. It was successfully applied to perform the pharmacokinetic and the bioavailability study. © 2020, Springer Science+Business Media, LLC, part of Springer Nature
  • Thumbnail Image
    Item
    Rivastigmine
    (Elsevier, 2021-01) Ezzat, Shahira M; Salem, Mohamed A.; El Mahdy, Nihal M.; Ragab, Mai F.
    Alzheimer's disease (AD) is a neurodegenerative dementing disease characterized by slowly increasing impairment in memory, cognition, speech, and behavioral functions, such as the recognition of objects and people, as a result of neuronal cell death. Acetylcholine (ACh) is a neurotransmitter that is implicated in several processes, including learning and regulation of cognitive functions. To date, there is no cure for AD; all available treatments aim merely to alleviate the symptoms of this condition. This can be achieved by improving neurotransmission by inhibiting the breakdown of ACh, thus improving attention, memory, learning, and cognitive functions. In this chapter, we will provide an overview of rivastigmine, an acetylcholinesterase inhibitor ratified by the Food and Drug Administration to control mild to moderate stages of AD.